Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer

US9896445B2 · kind B2 · utility

Assignee

• Ansana BioSciences, LLC · US

Inventors

• Aranapakam Venkatesan · Chadds Ford, US
• Scott K. Thompson · Phoenixville, US
• Roger Smith · Madison, US
• Sanjeeva P. Reddy · Chester Springs, US
• Raghava Reddy Kethiri · Noida, IN
• Purushottam Dewang · Kanchinakote, IN
• Gurulingappa Hallur · Kanchinakote, IN
• Chandrika Mulakala · Bengaluru, IN
• Ramesh Mullangi · Bengaluru, IN
• Mohd Zainuddin

Key dates

• Filing date: Jun 15, 2016
• Grant date: Feb 20, 2018
• Expiry date: Jun 15, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D405/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and R1 to R8 are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.